Role of Human Chorionic Gonadotrophin Compared to 17-Alpha-Hydroxyprogesterone in the Management of Threatened Abortion: Experience in a Military Hospital in Dhaka, Bangladesh

Background: Threatened abortion is the most common complication in the first half of gestation. Spontaneous abortion occurs in less than 30% of the women who experience threatened abortion. In order to prevent pregnancy loss several supportive therapies including hormonal therapy like human chorionic gonadotropin (hCG) or 17-alpha-hydroxyprogesterone (progesterone) have been advocated. The exogenous administration of hCG is aimed at stimulating and therefore optimizing progesterone production. Aim of this study was to compare the efficacy of supportive therapy with hCG and progesterone in women with threatened abortion. Methods: This prospective study was carried out in the department of obstetrics and gynecology of the Combined Military hospital (CMH), Savar, Dhaka, Bangladesh from July 2016 to June 2017. One hundred pregnant patients admitted with the history of per vaginal bleeding before 20 weeks of gestation without having any other co-morbidity were included in this study. Patients were randomized to two treatment groups. The participants in group A (52, 52%) received injection hCG weekly while those in group B (48, 48%) received injection progesterone from recruitment up until 20 weeks of gestation. Further USG were performed one week and four weeks after recruitment to the study and again at 20 weeks and subsequently when indicated. The final outcome of pregnancy were recorded and analyzed. Results: Among 100 patients majority belonged to the 26-30 year age group. Mean age of the patients was 27.2±10.5 years. There was not much significant difference between the groups in terms of parity. More than 75% of patients in both the groups presented before 16 weeks of gestation with threatened abortion. In both the groups more than 75% of the patients had previous history of pregnancy loss. In terms of pregnancy outcome more patients in hCG group had live pregnancy than progesterone group (88.5% vs 66.7%) (p=0.012). Out of 46 live birth in hCG group, 4 (7.7%) were preterm labor between 31-35 weeks of pregnancy and one baby died in neonatal ICU, one died at 31 weeks of gestation which was delivered by vaginally. On the other hand out of 32 live birth in progesterone group, there was 3 (6.3%) preterm labor. Growth retardation was less in hCG group compared to progesterone group (9.6% vs 14.6%). However cesarean section rate was high in both the groups. Conclusion: Treatment with injection hCG has better pregnancy outcome than that of injection17-alphahydroxyprogesterone in early pregnancy with threatened abortion of unexplained cause. Birdem Med J 2019; 9(1): 7-10

Download Full-text

Predictors of Pregnancy Outcome in Essential Thrombocythemia: A Single Institution Study of 63 Pregnancies.

Blood ◽

10.1182/blood.v112.11.1752.1752 ◽

2008 ◽

Vol 112 (11) ◽

pp. 1752-1752

Author(s):

Naseema Gangat ◽

Alexandra Wolanskyj ◽

Susan Schwager ◽

Ayalew Tefferi

Keyword(s):

Platelet Count ◽

Pregnancy Outcome ◽

Live Birth ◽

Pregnancy Loss ◽

Leukocyte Count ◽

Patient Characteristics ◽

First Trimester ◽

Aspirin Therapy ◽

Increased Risk ◽

History Of

Abstract Background: Essential thrombocythemia (ET) frequently occurs in women of childbearing age. Recently, an increased risk of pregnancy complications was reported in patients with ET carrying the JAK2V617F mutation (Passamonti et al. Blood. 2007;110:485). In the current study, we sought to validate this observation as well as identify other predictors of pregnancy loss in ET. Methods: Data was abstracted from the medical records of a consecutive cohort of patients with WHO-defined ET seen at the Mayo Clinic. Patient characteristics and pregnancy outcome are summarized using descriptive statistics. The analysis of risk factors associated with pregnancy complications was carried out by both univariate and multivariate analyses. Results: i) Patient characteristics at ET diagnosis A total of 63 pregnancies were recorded in 36 women at or after their diagnosis of ET. At diagnosis of ET, median (range) values were: age 26 years (15–36), platelet count 1350 x 109/L (683–3300), hemoglobin level 13.3 g/dL (10.5–16) and leukocyte count 9.3 x109/L (5–26.9). JAK2V617F mutation analysis was performed in 20 patients; half were positive. Only 5 patients had a history of thrombosis at diagnosis. Follow-up after ET diagnosis was for a median of 82.9 months (range, 6.5–340.8 months). ii) Outcome of first pregnancy at or after diagnosis of ET A total of 36 first pregnancies were documented at or after the diagnosis of ET. At the time, median (range) values were: time from diagnosis 25.5 months (0–155), age 28 years (20–36), platelet count 840 x 109/L (255–1998), hemoglobin 12.9 g/dl (9–16.6) and leukocyte count 8.4 x109/L (6.6–19.8). Seven of the 36 (19%) women were receiving cytoreductive therapy at time of conception: anagrelide (n=4), interferon (n=1), hydroxyurea (n=1) and radiophosphorus (n=1). Aspirin therapy was documented in 53% of the women at time of conception and in 69% during the first trimester of their pregnancy. Among the 36 first pregnancies, 61% (n=22) resulted in live birth and 39% (n=14) in fetal loss. Twelve of the 14 pregnancy losses occurred during the first trimester (10 spontaneous miscarriages, 1 ectopic pregnancy and 1 therapeutic abortion) and the remaining two during the second trimester. Maternal complications occurred in 11% (n=4) of pregnancies and included pre-eclampsia (n=1), hematoma after Cesarean-section (n=2) and post-partum hemorrhage (n=1). iii) Predictors of first pregnancy outcome in ET Pregnancy outcome, in terms of live birth versus miscarriage did not correlate with age (p=0.27), presence of cardiovascular risk factor (p=0.76), platelet count (p=0.49), leukocyte count (p=0.67) or hemoglobin level (p=0.31). Similarly, pregnancy loss was similar between JAK2V617F-positive (4 of 10 pregnancies) and JAK2V617F-negative (4 of 10 pregnancies) patients (p>0.9). Furthermore, among 5 cases of 3 consecutive miscarriages, 4 were JAK2V617F-negative. Interestingly, the rate of pregnancy loss was only 21% among 24 patients receiving aspirin therapy during the first trimester as compared to 75% among the 12 patients in whom no such treatment was documented (p=0.002). iv) Second and subsequent pregnancy outcome Seventeen second pregnancies were recorded; 71% (n=12) resulted in live birth that included 8 of 9 patients with successful and 4 of 8 with unsuccessful first pregnancies (p=0.07). The trend was similar among 7 third pregnancies, which resulted in only one live birth; 5 of the 6 fetal losses occurred in women with history of first pregnancy loss (p=0.09). Conclusion: The current study does not support the recently communicated association between the presence of JAK2V617F and increased risk of pregnancy loss in ET. Instead, two parameters of potential importance for predicting pregnancy outcome in ET were identified; the occurrence of a miscarriage might be a marker for a similar event during subsequent pregnancies whereas aspirin therapy during the first trimester might be beneficial.

Download Full-text

Dysmorphic Uteri: Obstetric Results after Hysteroscopic Office Metroplasty in Infertile and Recurrent Pregnancy Loss Patients. A Prospective Observational Study

Journal of Clinical Medicine ◽

10.3390/jcm9092857 ◽

2020 ◽

Vol 9 (9) ◽

pp. 2857

Author(s):

Mónica Sánchez-Santiuste ◽

Mar Ríos ◽

Laura Calles ◽

Reyes de la Cuesta ◽

Virginia Engels ◽

...

Keyword(s):

Live Birth ◽

Pregnancy Loss ◽

Birth Rate ◽

Recurrent Pregnancy Loss ◽

Live Birth Rate ◽

Obstetric Outcomes ◽

Significant Difference ◽

History Of ◽

The Difference ◽

Infertile Patients

To compare the obstetric results achieved after hysteroscopic office metroplasty (HOME-DU) in infertile and recurrent pregnancy loss (RPL) patients diagnosed with dysmorphic uterus, women hysteroscopically diagnosed with dysmorphic uterus who underwent uterine-enlargement metroplasty were prospectively enrolled from June 2016 until April 2020. Patients were followed up and obstetric outcomes were recorded (pregnancy and live birth rate). Sixty-three women (30 infertile; 33 RPL) were enrolled, of which 48 became pregnant post-HOME-DU, with an overall pregnancy rate of 76.2% (66.7% among infertile participants; 84.9% among those with RPL). Overall, 64.3% (n = 36/63) achieved live birth. Among infertile women, 62.07% (n = 18/29) achieved live birth, as well as 66.7% of women with RPL (n = 18/27). The difference in live birth rates between both cohorts was 4.6% (p > 0.05). The rate of miscarriage amongst infertile patients was 3.3% (n = 1/30) and 12.1% amongst women with RPL (n = 4/33). Office metroplasty via the HOME-DU technique improves obstetric results (namely increasing live birth rate) in patients with dysmorphic uterus and a history of reproductive failure. No significant difference was found in the clinical efficacy of HOME-DU in infertile and RPL patients.

Download Full-text

Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany

Reproductive Biology and Endocrinology ◽

10.1186/s12958-021-00768-3 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Klaus F. Bühler ◽

Robert Fischer ◽

Patrice Verpillat ◽

Arthur Allignol ◽

Sandra Guedes ◽

...

Keyword(s):

Assisted Reproductive Technology ◽

Live Birth ◽

Pregnancy Loss ◽

Follicle Stimulating Hormone ◽

Reproductive Technology ◽

Clinical Pregnancy ◽

Human Menopausal Gonadotropin ◽

Ongoing Pregnancy ◽

Complete Cycle ◽

Significant Difference

Abstract Background This study compared the effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa; GONAL-f®) with urinary highly purified human menopausal gonadotropin (hMG HP; Menogon HP®), during assisted reproductive technology (ART) treatments in Germany. Methods Data were collected from 71 German fertility centres between 01 January 2007 and 31 December 2012, for women undergoing a first stimulation cycle of ART treatment with r-hFSH-alfa or hMG HP. Primary outcomes were live birth, ongoing pregnancy and clinical pregnancy, based on cumulative data (fresh and frozen-thawed embryo transfers), analysed per patient (pP), per complete cycle (pCC) and per first complete cycle (pFC). Secondary outcomes were pregnancy loss (analysed per clinical pregnancy), cancelled cycles (analysed pCC), total drug usage per oocyte retrieved and time-to-live birth (TTLB; per calendar week and per cycle). Results Twenty-eight thousand six hundred forty-one women initiated a first treatment cycle (r-hFSH-alfa: 17,725 [61.9%]; hMG HP: 10,916 [38.1%]). After adjustment for confounding variables, treatment with r-hFSH-alfa versus hMG HP was associated with a significantly higher probability of live birth (hazard ratio [HR]-pP [95% confidence interval (CI)]: 1.10 [1.04, 1.16]; HR-pCC [95% CI]: 1.13 [1.08, 1.19]; relative risk [RR]-pFC [95% CI]: 1.09 [1.05, 1.15], ongoing pregnancy (HR-pP [95% CI]: 1.10 [1.04, 1.16]; HR-pCC [95% CI]: 1.13 [1.08, 1.19]; RR-pFC [95% CI]: 1.10 [1.05, 1.15]) and clinical pregnancy (HR-pP [95% CI]: 1.10 [1.05, 1.14]; HR-pCC [95% CI]: 1.14 [1.10, 1.19]; RR-pFC [95% CI]: 1.10 [1.06, 1.14]). Women treated with r-hFSH-alfa versus hMG HP had no statistically significant difference in pregnancy loss (HR [95% CI]: 1.07 [0.98, 1.17], were less likely to have a cycle cancellation (HR [95% CI]: 0.91 [0.84, 0.99]) and had no statistically significant difference in TTLB when measured in weeks (HR [95% CI]: 1.02 [0.97, 1.07]; p = 0.548); however, r-hFSH-alfa was associated with a significantly shorter TTLB when measured in cycles versus hMG HP (HR [95% CI]: 1.07 [1.02, 1.13]; p = 0.003). There was an average of 47% less drug used per oocyte retrieved with r-hFSH-alfa versus hMG HP. Conclusions This large (> 28,000 women), real-world study demonstrated significantly higher rates of cumulative live birth, cumulative ongoing pregnancy and cumulative clinical pregnancy with r-hFSH-alfa versus hMG HP.

Download Full-text

Effects of Pregnancy Loss on Subsequent Postpartum Mental Health: A Prospective Longitudinal Cohort Study

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18042179 ◽

2021 ◽

Vol 18 (4) ◽

pp. 2179

Author(s):

David C. Reardon ◽

Christopher Craver

Keyword(s):

Mental Health ◽

Risk Factor ◽

Live Birth ◽

Pregnancy Loss ◽

Mental Health Problems ◽

Psychiatric Treatment ◽

Reproductive Services ◽

History Of ◽

Mental Health Treatments ◽

Prospective Longitudinal

Pregnancy loss, natural or induced, is linked to higher rates of mental health problems, but little is known about its effects during the postpartum period. This study identifies the percentages of women receiving at least one postpartum psychiatric treatment (PPT), defined as any psychiatric treatment (ICD-9 290-316) within six months of their first live birth, relative to their history of pregnancy loss, history of prior mental health treatments, age, and race. The population consists of young women eligible for Medicaid in states that covered all reproductive services between 1999–2012. Of 1,939,078 Medicaid beneficiaries with a first live birth, 207,654 (10.7%) experienced at least one PPT, and 216,828 (11.2%) had at least one prior pregnancy loss. A history of prior mental health treatments (MHTs) was the strongest predictor of PPT, but a history of pregnancy loss is also another important risk factor. Overall, women with a prior pregnancy loss were 35% more likely to require a PPT. When the interactions of prior mental health and prior pregnancy loss are examined in greater detail, important effects of these combinations were revealed. About 58% of those whose first MHT was after a pregnancy loss required PPT. In addition, over 99% of women with a history of MHT one year prior to their first pregnancy loss required PPT after their first live births. These findings reveal that pregnancy loss (natural or induced) is a risk factor for PPT, and that the timing of events and the time span for considering prior mental health in research on pregnancy loss can significantly change observed effects. Clinicians should screen for a convergence of a history of MHT and prior pregnancy loss when evaluating pregnant women, in order to make appropriate referrals for counseling.

Download Full-text

Progestogens for treatment and prevention of pregnancy disorders

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci.2010.069 ◽

2010 ◽

Vol 3 (3) ◽

Author(s):

Adolf E. Schindler

Keyword(s):

Premature Birth ◽

Previous History ◽

First Trimester ◽

Study Groups ◽

Treatment And Prevention ◽

Maternal Immune System ◽

Hydroxyprogesterone Caproate ◽

History Of ◽

Threatened Abortion ◽

In Pregnancy

AbstractProgesterone appears to be the dominant hormone not only establishing a proper secretory endometrial development but also adequate decidualization to establish pregnancy and sustain pregnancy development. Progesterone is the natural immunoregulator to control the maternal immune system and not to reject the allogeneic fetus. There are two sources of progesterone: corpus luteum first and placenta later. Three progestogens can be used in pregnancy: (i) progesterone (per os, intravaginal and intramuscular), (ii) dydrogesterone (per os), and (iii) 17α-hydroxyprogesterone caproate (intramuscular). There are three indications, for which these progestogens can be clinically used either for treatment or prevention: (i) first trimester threatened and recurrent (habitual) abortion, (ii) premature labor/premature birth, and (iii) pre-eclampsia (hypertension in pregnancy). The available data are limited and only partially randomized. In threatened abortion the use of progesterone, dydrogesterone and 17α-hydroxyprogesterone caproate leads to a significant improved outcome, when at the time of threatened abortion a viable fetus has been ascertained by ultrasound. For prevention of recurrent abortion there are also some data indicating a significant effect compared with women without progestogen treatment. Prevention of preterm birth by progestogens (progesterone vaginally, orally and 17α-hydroxyprogesterone caproate intramuscularly) was significantly effective. The main study groups include pregnant women with a previous history of premature birth. However, also in women with shortened cervix use of progesterone seems to be helpful. The studies done so far in women with risk factors for pre-eclampsia or established pre-eclampsia were based on parenteral progesterone application. However, new studies are urgently needed.

Download Full-text

The Deferred Embryo Transfer Strategy Seems Not to be a Good Option After Repeated IVF/ICSI Cycle Failures

Reproductive Sciences ◽

10.1177/1933719118811648 ◽

2018 ◽

Vol 26 (9) ◽

pp. 1210-1217 ◽

Cited By ~ 1

Author(s):

Mathilde Bourdon ◽

Pietro Santulli ◽

Yulian Chen ◽

Catherine Patrat ◽

Khaled Pocate-Cheriet ◽

...

Keyword(s):

Logistic Regression ◽

Embryo Transfer ◽

Live Birth ◽

Birth Rate ◽

Previous History ◽

Multivariate Logistic Regression Analysis ◽

Live Birth Rate ◽

Multivariate Logistic Regression ◽

Icsi Cycle ◽

Significant Difference

Objective: The aim of this study was to assess whether a deferred frozen–thawed embryo transfer (Def-ET) offers any benefits compared to a fresh ET strategy in women who have had 2 or more consecutive in vitro fertilization (IVF)/intracytoplasmic injection (ICSI) cycle failures. Design: An observational cohort study in a tertiary referral care center including 416 cycles from women with a previous history of 2 or more consecutive IVF/ICSI failures cycles. Both Def-ET and fresh ET strategies were compared using univariate and multivariate logistic regression models. The main outcome measured was the cumulative live birth rate (CLBR). Results: A total of 416 cycles were included in the analysis: 197 in the fresh ET group and 219 in the Def-ET group. The CLBR was not significantly different between the fresh and Def-ET groups (58/197 [29.4%] and 57/219 [26.0%], respectively, P = .437). In addition, after the first ET, there was no significant difference in the live birth rate between the fresh ET and Def-ET groups (50/197 [25.4%] vs 44/219 [20.1%], respectively). Multivariate logistic regression analysis indicated that compared to the fresh strategy, the Def-ET strategy was not associated with a higher probability of live birth. Conclusions: In cases with 2 or more consecutive prior IVF/ICSI cycle failures, a Def-ET strategy did not result in better ART outcomes than a fresh ET strategy.

Download Full-text

Comparison of Maternal and Fetal Outcomes in Parturients With and Without a Diagnosis of Gestational Diabetes

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics ◽

10.1055/s-0039-1696947 ◽

2019 ◽

Vol 41 (11) ◽

pp. 647-653 ◽

Cited By ~ 1

Author(s):

Inês Carolina Siqueira Freitas ◽

Micheli Cristiane Hintz ◽

Larissa Chaiane Orth ◽

Tamara Gonçalves da Rosa ◽

Betine Moehlecke Iser ◽

...

Keyword(s):

Family History ◽

Gestational Diabetes ◽

Statistical Significance ◽

Positive Family History ◽

Previous History ◽

Diabetes Diagnosis ◽

Fetal Outcomes ◽

Family History Of Diabetes ◽

Significant Difference ◽

History Of

Abstract Objective The present study aims to compare the maternal and fetal outcomes of parturients with and without a gestational diabetes diagnosis. Methods A case-control study including parturients with (cases) and without (control) a gestational diabetes diagnosis, who delivered at a teaching hospital in Southern Brazil, between May and August 2018. Primary and secondary data were used. Bivariate analysis and a backward conditional multivariate logistic regression were used to make comparisons between cases and controls, which were expressed by odds ratio (OR), with a 95% confidence interval (95%CI) and a statistical significance level of 5%. Results The cases (n = 47) were more likely to be 35 years old or older compared with the controls (n = 93) (p < 0.001). The cases had 2.56 times greater chance of being overweight (p = 0.014), and a 2.57 times greater chance of having a positive family history of diabetes mellitus (p = 0.01). There was no significant difference regarding weight gain, presence of a previous history of gestational diabetes, height, or delivery route. The mean weight at birth was significantly higher in the infants of mothers diagnosed with diabetes (p = 0.01). There was a 4.7 times greater chance of macrosomia (p < 0.001) and a 5.4 times greater chance of neonatal hypoglycemia (p = 0.01) in the infants of mothers with gestational diabetes. Conclusion Therefore, maternal age, family history of type 2 diabetes, obesity and pregestational overweightness are important associated factors for a higher chance of developing gestational diabetes.

Download Full-text

Pregnancy outcome following previous history of spontaneous abortion

Obsgyne Review: Journal of Obstetric and Gynecology ◽

10.17511/joog.2019.i01.10 ◽

2019 ◽

Vol 5 (1) ◽

pp. 53-58

Author(s):

Dr. Nehal N. ◽

◽

Dr. Sawant V ◽

Keyword(s):

Pregnancy Outcome ◽

Spontaneous Abortion ◽

Previous History ◽

History Of

Download Full-text

Factores de riesgo del síndrome confusional agudo en ancianos hospitalizados.

Ciencia e Innovación en Salud ◽

10.17081/innosa.2962 ◽

2018 ◽

Author(s):

Juan Rodado ◽

Irine Aragon

Keyword(s):

Risk Factors ◽

Previous History ◽

Source Population ◽

Co Morbidity ◽

Factores De Riesgo ◽

History Of ◽

Transversal Study ◽

Special Relevance ◽

Control Study

Background: Acute confusional syndrome is a current problem of special relevance among elderlypatients admitted to hospital medical services. The determination of its risk factors is an essential process in the development and implementation of programs to prevent this complication. Methods: With the mentioned aim we have carried out this case-control study as an analytical, observational, retrospective and transversal study, whose source population was integrated by 60 patients over age 65 according to inclusion and exclusion criteria and divided into two groups: with and without delirium. Discussion: Our analysis has confirmed the association between these factors and delirium: illness severity; previous history of Delirium (OR 10.6); mental status (OR 7.3); high risk medications (OR 6.9); renal failure (OR 6.5); medication at risk added (OR 6); physical status (OR 5.2); use of neuroleptics (OR5.1); anemia (OR 4.75); sodium alterations (OR 4.5); urinary catheter (OR 3.8); low albumin (OR 3.7); infection (OR 3.1). Conclusion: There is no relationship proved between acute confusional syndrom and the following factors: use of benzodiazepines, aggressive procedures, immobility, old age, dementia, diminished ADL skills, co-morbidity and polypharmacy, even if they have been identified as risk factors in previous studies. Hence, these results should be interpreted with caution.

Download Full-text